Malta - English - Medicines Authority

cis bio international route nationale 306-saclay, bp 32, 91192, gif-sur-yvette cedex, france - fluorocholine - solution for injection - fluorocholine (18-f) 225 mbq/ml - diagnostic radiopharmaceuticals

European Union - English - EMA (European Medicines Agency)

cis bio international - depreotide trifluoroacetate - radionuclide imaging - diagnostic radiopharmaceuticals - this medicinal product is for diagnostic use only.for scintigraphic imaging of suspected malignant tumours in the lung after initial detection, incombination with ct scan or chest x-ray, in patients with solitary pulmonary nodules.

European Union - English - EMA (European Medicines Agency)

cis bio international - samarium (153sm) lexidronam pentasodium - pain; cancer - therapeutic radiopharmaceuticals - quadramet is indicated for the relief of bone pain in patients with multiple painful osteoblastic skeletal metastases which take up technetium [99mtc]-labelled biphosphonates on bone scan.the presence of osteoblastic metastases which take up technetium [99mtc]-labelled biphosphonates should be confirmed prior to therapy.

European Union - English - EMA (European Medicines Agency)

cis bio international - yttrium (90y) chloride - radionuclide imaging - diagnostic radiopharmaceuticals - to be used only for the radiolabelling of carrier molecules which have been specifically developed and authorised for radiolabelling with this radionuclide.radiopharmaceutical precursor - not intended for direct application to patients.

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

cis bio international - thallous (201 tl) chloride 37 mbq/ml - solution for injection - 37 mbq/ml - thallium (tl-201) chloride 37 mbq/ml - thallium (201tl) chloride

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

cis bio international - fluorocholine (18 f) 225 mbq/ml - solution for injection - 225 mbq/ml - fluorocholine (f-18) 225 mbq/ml - fluoromethylcholine (18f)

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

cis bio international - fluorodopa (18 f) 90 mbq/ml - solution for injection - 90 mbq/ml - fluorodopa (f-18) - fluorodopa (18f)

United States - English - NLM (National Library of Medicine)

gland pharma limited - cisplatin (unii: q20q21q62j) (cisplatin - unii:q20q21q62j) - cisplatin 1 mg in 1 ml - cisplatin injection is indicated as therapy to be employed as follows: metastatic testicular tumors in established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. metastatic ovarian tumors in established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. an established combination consists of cisplatin and cyclophosphamide. cisplatin injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received cisplatin injection therapy. advanced bladder cancer cisplatin injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatmen

United States - English - NLM (National Library of Medicine)

athenex pharmaceutical division, llc. - cisplatin (unii: q20q21q62j) (cisplatin - unii:q20q21q62j) - cisplatin 1 mg in 1 ml - cisplatin injection is indicated as therapy to be employed as follows: in established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. in established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. an established combination consists of cisplatin and cyclophosphamide. cisplatin injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received cisplatin injection therapy. cisplatin injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy. cisplatin is contraindicated in patients with pre-existing renal i

United States - English - NLM (National Library of Medicine)

alvogen inc. - cisplatin (unii: q20q21q62j) (cisplatin - unii:q20q21q62j) - cisplatin 50 mg in 50 ml - cisplatin injection is indicated as therapy to be employed as follows: in established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. in established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. an established combination consists of cisplatin and cyclophosphamide. cisplatin injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received cisplatin injection therapy. cisplatin injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy. cisplatin is contraindicated in patients with pre-existing renal i